Author(s)
Skovlund S1, Gorbenko OV2, Richards DP3, Nafria B4, Delbecque L5, Deane KH6, Schroeder KB7, Sargeant I8, Hamoir AM8
1Aalborg University Hospital, Aalborg University, Aalborg, Denmark, 2ViiV Healthcare, London, UK, 3Clinical Trials Ontario, Toronto, ON, Canada, 4Sant Joan de Déu Research Foundation, Barcelona, Spain, 5S.A. Eli Lilly Benelux N.V., Brussels, Belgium, 6University of East Anglia, Norwich, UK, 7Parkinson’s Foundation, New York, NY, USA, 8Patient Focused Medicines Development, Brussels, Belgium
OBJECTIVES : To conduct a global consultation of perceived relevance and priority of patient engagement (PE) activities in medicines development across multiple stakeholder groups. METHODS : Patient Focused Medicines Development (PFMD, a global multistakeholder coalition) reviewed published literature (2011-2017) to identify a preliminary list of PE activities. A 22-question online survey covering each phase of medicines’ development was designed for stakeholders involved/experienced in PE in medicines development. Respondents were asked to prioritise listed PE activities at each phase, via questions related to communication, engagement, methodology and training/education. Consultation was conducted over 9 weeks (June-August 2018). RESULTS : 159 PE activities were included: research/discovery (n=35); preclinical (n=34); clinical (n=44); regulatory (n=22); post-approval (n=24). 183 respondents completed the survey, representing 10 different stakeholder groups and 26 countries (23% from outside EU-US axis). Respondents’ PE experience (per phase) was: 61% (early); 52% (preclinical); 61% (phase I-III); 34% (regulatory); 48% (post-approval). Overall, 87% of PE activities were rated as moderately/highly relevant. Prioritised PE activities (per phase) included: collection of patient insights on disease experience, use of patient experience to design research methodology (early); patient participation in design of patient information materials, trial design and operations (preclinical); patient participation in research questions, trial design, patient-reported outcomes methods design, study logistics and accessibility issues (phase I-III); testimony for public hearings and advisory committees, input to lay summaries and medical information (regulatory); patient community feedback including in post-marketing research, lay communication and outreach, adverse events reporting (post-approval). Activities rated highly relevant across phases included: understanding patient disease experience; lay patient communication and outreach; input into research aims and methodology. CONCLUSIONS : This global survey provides new insights to guide the focus of future PE implementation support efforts. PFMD and multistakeholder volunteers are facilitating co-creation of “how-to” modules for prioritised PE activities, using PFMD PE Quality Guidance methodology (Deane et al. ISPOR Europe 2018; poster PHP14).
Conference/Value in Health Info
2019-05, ISPOR 2019, New Orleans, LA, USA
Value in Health, Volume 22, Issue S1 (2019 May)
Code
PNS249
Topic
Patient-Centered Research
Topic Subcategory
Patient Engagement
Disease
No Specific Disease